Medical Pharmaceuticals

Curium Receives Positive CHMP Opinion of PYLCLARI® for Primary Staging of Patients With High-Risk PCa Prior to Initial Curative Therapy and to Localize Recurrence of PCa in Patients With a Suspected Recurrence Based on Increasing Serum Prostate-Specific Antigen (PSA) Levels After Primary Treatment With Curative Intent

f approved for Europe, PYLCLARI® (INN: Piflufolastat (18F) formerly known [...]

By |2023-05-26T14:09:26+00:00May 26, 2023|3rd Party Medical Device Industry News|Comments Off on Curium Receives Positive CHMP Opinion of PYLCLARI® for Primary Staging of Patients With High-Risk PCa Prior to Initial Curative Therapy and to Localize Recurrence of PCa in Patients With a Suspected Recurrence Based on Increasing Serum Prostate-Specific Antigen (PSA) Levels After Primary Treatment With Curative Intent
Read More

DISCLAIMER

JOIN OUR MAILING LIST

© YOUNG & PARTNERS LLC   |   535 Fifth Avenue, 4th Floor, New York, New York 10017 | 212-682-5555

Go to Top